A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment.
about
Modulation of Protein-Protein Interactions for the Development of Novel TherapeuticsDirect and Propagated Effects of Small Molecules on Protein-Protein Interaction NetworksSmall-molecule SMAC mimetics as new cancer therapeuticsApoptotic agentsTargeting the apoptosis pathway in hematologic malignanciesRIP2 activity in inflammatory disease and implications for novel therapeuticsDiscovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152)The paradox role of caspase cascade in ionizing radiation therapyOrder and disorder in large multi-site docking proteins of the Gab family--implications for signalling complex formation and inhibitor design strategiesExpedient synthesis of highly potent antagonists of inhibitor of apoptosis proteins (IAPs) with unique selectivity for ML-IAPGenetic visualization of protein interactions harnessing liquid phase transitionsA covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination.Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)Small-molecule inhibitors of protein-protein interactions: progressing toward the reality.Targeting protein-protein interactions as an anticancer strategyMechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells.Potent bivalent Smac mimetics: effect of the linker on binding to inhibitor of apoptosis proteins (IAPs) and anticancer activity.Potent and selective small-molecule inhibitors of cIAP1/2 proteins reveal that the binding of Smac mimetics to XIAP BIR3 is not required for their effective induction of cell death in tumor cells.Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study.A novel antagonist to the inhibitors of apoptosis (IAPs) potentiates cell death in EGFR-overexpressing non-small-cell lung cancer cellsThe Proapoptotic F-box Protein Fbxl7 Regulates Mitochondrial Function by Mediating the Ubiquitylation and Proteasomal Degradation of SurvivinLipid-conjugated Smac analogues.LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signalingSmall molecules, big targets: drug discovery faces the protein-protein interaction challenge.IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis.Targeting inhibitors of apoptosis proteins (IAPs) for new breast cancer therapeuticsSMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells.Smac127 Has Proapoptotic and Anti-Inflammatory Effects on Rheumatoid Arthritis Fibroblast-Like SynoviocytesTargeting Inhibitor of Apoptosis Proteins Protects from Bleomycin-Induced Lung Fibrosis.AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer.Imaging caspase-3 activation as a marker of apoptosis-targeted treatment response in cancer.Pathophysiological Significance of Hepatic ApoptosisOvercoming resistance to TRAIL-induced apoptosis in solid tumor cells by simultaneously targeting death receptors, c-FLIP and IAPs.X-linked inhibitor of apoptosis regulates lung fibroblast resistance to Fas-mediated apoptosis.IAP proteins as targets for drug development in oncologyA potent bivalent Smac mimetic (SM-1200) achieving rapid, complete, and durable tumor regression in mice.Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivationIAP antagonists sensitize murine osteosarcoma cells to killing by TNFαLoss of XIAP facilitates switch to TNFα-induced necroptosis in mouse neutrophils.Participation of c-FLIP in NLRP3 and AIM2 inflammasome activation.
P2860
Q26775356-7EF8F3CB-117A-482B-9E1F-2373087407A3Q26784027-85B62B4F-9506-484F-BE9D-D99A56616AFDQ26864204-49A12876-799E-4781-91B4-72AD3B422FCBQ27016160-1CFDFF16-A4F6-4E8C-80D5-134BC57E4A13Q27024422-CB3561BB-C21A-4E2B-8095-1C7FDC0B4EE5Q27025050-11B28297-83D4-48E6-8A8F-5063E8A34A10Q27678027-E60AA8E6-4197-43C3-9644-23877DCB42D8Q28079723-7A6D945E-BBC9-40D3-AE37-FBC6E90FC3C4Q28248627-0A978AF9-11C5-418A-B8D8-503886F53680Q28283505-8CDF99B0-084B-4F52-B88D-8D6188D43BF8Q30845173-6D380315-D686-4FF6-9620-9B142C290A30Q33626131-43623582-AA31-41AE-9853-87D838D7A587Q33841579-F910D17B-A9AA-4E54-8E36-F4EA8B5079A8Q34263719-39E269EA-18CD-4938-8D24-72853E90B04AQ34347892-AB39D589-BB95-49CC-8C62-B85A1038E4AEQ34912378-39A731B6-19A8-4E31-9F0C-3EBA55D1109AQ35024837-DDBF0C9C-6224-47D2-9A13-691BEC6ED307Q35072876-8A28698C-7A59-4CF9-94AD-62EEEF788903Q35193374-E2AC791A-A8A1-4E9F-B967-B30292DAB6F5Q35338435-2F035357-4A18-4740-B0BE-C82E27656C63Q35583027-0496DA5D-AD3D-4A86-BC95-06FFB0DF32EEQ35780628-11C7D37A-2E90-498D-B217-899706C7BE60Q35803259-8899F152-85CA-481A-818F-BBF10A1DC839Q35981250-22EFEADA-6F53-4E65-8A95-D180C8C4BCA5Q36103378-35E333F0-26F9-463F-87CE-79E8C70DEE9AQ36501732-62364D84-238F-4F2B-8A40-24CE396BD679Q36545758-1949BCCF-1DCB-4893-856E-6ED625F7AE5DQ36637550-EFCCA67B-7A94-43E9-8916-B6C01A0A915FQ36765978-824F3973-DC99-4A16-BE4E-E0625BD88AF7Q36919815-67D4E136-244B-4A34-99FB-E55E41B886A7Q36920403-ECF5BA1B-86C7-433F-AF60-D595C3F7AAE8Q36961965-5E7E3011-F4D8-4DD6-A65A-953C8C54F8A9Q36992161-BBD4B381-FB81-48BF-9ACD-7E4744B8EA0CQ37056479-E5AA0DE3-1443-4BED-BEF4-8DB3BDAABF5BQ37209606-87D436AB-EC66-4695-9234-12C1D5EE157CQ37249659-B919AF0D-EFC4-43E5-AEA0-45F96D83D982Q37299698-24249E2F-E6E3-4001-970B-7328ADD64E60Q37376164-07A61005-ED03-45FB-9B7C-30100C5DA578Q37465889-A8BFBFF7-894C-4CFD-B42F-7E55E2B30942Q37578811-C90616AA-8A62-4523-BAE8-E3D9AE09E98D
P2860
A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
A potent and orally active ant ...... elopment for cancer treatment.
@ast
A potent and orally active ant ...... elopment for cancer treatment.
@en
type
label
A potent and orally active ant ...... elopment for cancer treatment.
@ast
A potent and orally active ant ...... elopment for cancer treatment.
@en
prefLabel
A potent and orally active ant ...... elopment for cancer treatment.
@ast
A potent and orally active ant ...... elopment for cancer treatment.
@en
P2093
P2860
P356
P1476
A potent and orally active ant ...... elopment for cancer treatment.
@en
P2093
Chao-Yie Yang
Dajun Yang
Donna McEachern
Haiying Sun
Jianfeng Lu
Lance Leopold
P2860
P304
P356
10.1021/JM101505D
P407
P577
2011-03-28T00:00:00Z